SELLAS Life Sciences shares plunge 19%: What triggered the sharp sell-off?
SELLAS Life Sciences shares plunged nearly 20% after the biotechnology company priced a $150 million public offering at $13 per share, a discount of around 28% to its previous close. The sell-off followed a sharp rally triggered by positive Phase 3 REGAL trial results for its experimental leukemia vaccine.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Regal Entertainment & Consultants (REGAL).
- Category: Stocks.
Why it matters
A routine update for Regal Entertainment & Consultants. Use the price and stock snapshot to gauge how the market is responding.







